C-Met expression and MET amplification in malignant pleural mesothelioma

Melanie C. Bois, Aaron Mansfield, William R. Sukov, Sarah M. Jenkins, Justin C. Moser, Christopher A. Sattler, Carin Y. Smith, Julian R Molina, Tobias D Peikert, Anja Roden

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


c-Met is a receptor tyrosine kinase shown to be overexpressed in malignant pleural mesothelioma (MPM). Whereas MET mutations have been identified in 3%-16% of MPMs, MET amplification has recently been reported in a single epithelioid MPM. We studied c-Met expression and MET amplification in a large MPM cohort and correlated results with morphologic and clinical features. We report the first case of MET amplification in sarcomatoid MPM. MPMs from surgical pathology files (1989-2014) were reviewed. c-Met immunohistochemistry was performed. Staining intensity and distribution were multiplied (H-score). Staining localization (cytoplasmic and/or membranous) was noted. Fluorescence in situ hybridization was performed using probes for MET and centromere 7. One hundred forty-nine patients (median age, 68.0 years; interquartile range, 61-75) had epithelioid (n = 97), biphasic (n = 18), or sarcomatoid (n = 34) MPM. Median follow-up was 10.1 months (range, 0.1-222.5). One hundred thirty patients died of disease; 2 were alive with disease. c-Met was expressed in 147 MPMs. c-Met staining intensity, distribution, and H-score differed among the histologic subtypes (P =.015; P =.0001, and P =.0005, respectively), but none were predictive of survival. Epithelioid subtype had greater c-Met expression. MET amplification was identified in 1 sarcomatoid MPM and MET duplication in 1 epithelioid MPM; both had poor outcomes. Chromosome 7 aneusomy was observed in 54 of 144 (37.5%) MPMs and associated with decreased overall survival in sarcomatoid MPMs (hazard ratio = 2.81; 95% confidence interval, 1.21-6.51; P =.01). In conclusion, c-Met is expressed in MPM, with significant differences in expression among histologic subtypes. MET amplification is a rare event in MPM, making it an unlikely common pathogenesis for c-Met expression.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalAnnals of Diagnostic Pathology
StatePublished - Aug 1 2016


  • c-Met
  • Mesothelioma
  • MET
  • Receptor tyrosine kinase
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'C-Met expression and MET amplification in malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this